Nonimmunological release of histamine from rat mast cells elicited by antineoplastic agents: effect of drug combinations.

Abstract:

:We studied the release of histamine elicited by some antineoplastic drugs in rat pleural and peritoneal mast cells. The drugs tested included the antibiotic mitomycin; the anthracyclines daunorubicin, doxorubicin, and epirubicin; the glycopeptide bleomycin; the chromopeptide dactinomycin; the platinum coordination complexes carboplatin and cisplatin; and the anthracenedione mitoxantrone. Mitomycin and bleomycin failed to elicit any release of histamine, whereas all of the other drugs induced histamine release from either pleural or peritoneal mast cells, the release being independent of extracellular calcium. The results indicate that antineoplastic drugs activate histamine release in a manner similar to that shown by compound 48/80, which may contribute to some of their secondary effects.

authors

Botana LM,Arnaez E,Vieytes MR,Alfonso A,Louzao MC

doi

10.1007/BF00685603

keywords:

subject

Has Abstract

pub_date

1992-01-01 00:00:00

pages

487-90

issue

6

eissn

0344-5704

issn

1432-0843

journal_volume

30

pub_type

杂志文章
  • Uptake of free and DNA-bound daunorubicin and doxorubicin into human leukemic cells.

    abstract::Leukemic cells from seven patients with acute nonlymphoblastic leukemia and granulocytes, and mononuclear cells from three healthy controls were isolated by centrifugation on metrozoate-dextran. The intracellular accumulation of both the free and DNA-bound forms of daunorubicin and doxorubicin was studied in vitro. Th...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00253105

    authors: Paul C,Peterson C,Gahrton G,Lockner D

    更新日期:1979-01-01 00:00:00

  • Comparison of the efficacy of tropisetron versus a metoclopramide cocktail based on the intensity of cisplatin-induced emesis.

    abstract::Cisplatin-induced emesis is one of the most feared side effects in cancer treatment. High-dose metoclopramide may prevent only 30-40% of cases of acute emesis. Investigations to test the efficacy of new antiemetics are mandatory. We compared the efficacy, toxicity, and patients' preference for tropisetron, a new 5-hyd...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF00688329

    authors: Chang TC,Hsieh F,Lai CH,Tseng CJ,Cheng HH,Li CL,Michael BJ,Soong YK

    更新日期:1996-01-01 00:00:00

  • Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations.

    abstract:PURPOSE:Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are key drugs in the treatment of non-small cell lung cancer (NSCLC) harboring EGFR activating mutations. We assessed the efficacy and safety of one EGFR tyrosine kinase inhibitor, erlotinib, in elderly Japanese patients with EGFR-mutated NSCLC....

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s00280-015-2784-x

    authors: Inoue Y,Inui N,Asada K,Karayama M,Matsuda H,Yokomura K,Koshimizu N,Imokawa S,Yamada T,Shirai T,Kasamatsu N,Suda T

    更新日期:2015-07-01 00:00:00

  • Fluoropyrimidine therapy: hyperbilirubinemia as a consequence of hemolysis.

    abstract:BACKGROUND:Hemolytic anemia has been noted during treatment with a variety of chemotherapeutic agents. We observed mild compensated hemolytic anemia in a patient receiving capecitabine during a randomized, controlled trial of adjuvant therapy. In order to investigate the hypothesis that hemolysis is the underlying caus...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s00280-005-1011-6

    authors: Nikolic-Tomasevic Z,Jelic S,Cassidy J,Filipovic-Ljeskovic I,Tomasevic Z

    更新日期:2005-12-01 00:00:00

  • In vivo antitumor activity by 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone in a solid human carcinoma xenograft model.

    abstract::Previously, we showed that 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone (DMC), isolated from the buds of Cleistocalyx operculatus, significantly inhibited the growth of human liver cancer SMMC-7721 cells and could induce SMMC-7721 cells apoptosis in vitro. Here, we report the antitumor effects of DMC in vivo, usi...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-004-0917-8

    authors: Ye CL,Liu JW,Wei DZ,Lu YH,Qian F

    更新日期:2005-05-01 00:00:00

  • Impact of metronomic neoadjuvant chemotherapy on early tongue cancer.

    abstract:PURPOSE:A metronomic schedule of chemotherapy (resulting in a greater frequency of drug delivery) has shown efficacy in head and neck cancer. Our aim was to investigate the overall survival in tongue cancer patients with metronomic neoadjuvant chemotherapy with bleomycin compared to those with surgery alone. METHODS:I...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-016-3141-4

    authors: Kina S,Nakasone T,Kinjo T,Maruyama T,Kawano T,Arasaki A

    更新日期:2016-10-01 00:00:00

  • Efficacy of SSG and SSG/IFNalpha2 against human prostate cancer xenograft tumors in mice: a role for direct growth inhibition in SSG anti-tumor action.

    abstract:BACKGROUND:Pre-clinical activity of SSG against melanoma and renal cancer has been identified recently although the drug's mechanism of action and activity against tumors of additional histological-types remain undefined. METHODS:The effects of SSG and SSG combination with other agents on DU145 human prostate carcinom...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-006-0378-3

    authors: Li J,Lindner DJ,Farver C,Borden EC,Yi T

    更新日期:2007-08-01 00:00:00

  • Successful treatment of a patient with acute nonlymphoblastic leukemia (ANLL) and anthracycline cardiomyopathy with 4' (9-acridinylamino) methanesulfon-m-anisidide (AMSA).

    abstract::A patient with acute nonlymphoblastic leukemia in relapse and anthracycline cardiomyopathy was treated with AMSA in combination with cytosine arabinoside and thioguanine (AAT). Induction of remission was accomplished after one course of therapy without development of congestive heart failure. Radionuclide studies done...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00257232

    authors: Fanucchi MP,Arlin ZA

    更新日期:1982-12-01 00:00:00

  • Camptothecin analogs with enhanced activity against human breast cancer cells. I. Correlation of potency with lipophilicity and persistence in the cleavage complex.

    abstract::The effect of 7-alkyl substitutions on growth inhibition in seven Camptothecin (CPT) ring systems with various groups at the ten position was evaluated in three human breast cancer cell lines that model (1) hormone-sensitive (MCF-7/wt), (2) hormone insensitive (MDA-MB-231), or (3) alkylator-resistant (MCF-7/4-hc) form...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-005-0007-6

    authors: Adams DJ,da Silva MW,Flowers JL,Kohlhagen G,Pommier Y,Colvin OM,Manikumar G,Wani MC

    更新日期:2006-01-01 00:00:00

  • Phase I study of non-pegylated liposomal doxorubicin in children with recurrent/refractory high-grade glioma.

    abstract:PURPOSE:To determine the maximum recommended dose (RD) and pharmacokinetics of Myocet®, a non-pegylated liposomal doxorubicin, in children. METHODS:Eligible patients were children with refractory high-grade glioma who had received prior chemotherapy and radiotherapy but no anthracyclines. Cohorts of at least three pat...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-015-2781-0

    authors: Chastagner P,Devictor B,Geoerger B,Aerts I,Leblond P,Frappaz D,Gentet JC,Bracard S,André N

    更新日期:2015-08-01 00:00:00

  • Preclinical pharmacology of 2-methoxyantimycin A compounds as novel antitumor agents.

    abstract:PURPOSE:The present study was designed to determine pharmacological and biochemical properties of 2-methoxyantimycin A analogs (OMe-A1, OMe-A2, OMe-A3, and OMe-A5), which are novel antitumor compounds, and provide a basis for future pharmaceutical development, preclinical evaluation, and clinical trials. METHODS:A hig...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-004-0978-8

    authors: Wang H,Li M,Rhie JK,Hockenbery DM,Covey JM,Zhang R,Hill DL

    更新日期:2005-09-01 00:00:00

  • An appraisal of subcutaneous trastuzumab: a new formulation meeting clinical needs.

    abstract::Trastuzumab has deeply and radically changed the course of HER2-positive breast cancer disease. The recent development of a subcutaneous (SC) formulation of trastuzumab is an important step towards improved patients' care. SC trastuzumab at a fixed dose of 600 mg administered every 3 weeks for about 5 min provides a v...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-013-2289-4

    authors: Launay-Vacher V

    更新日期:2013-12-01 00:00:00

  • Phase II trial of gemcitabine and docetaxel in patients with completely resected stage IIA-IIIA non-small-cell lung cancer.

    abstract:BACKGROUND:Few clinical phase II studies using non-platinum doublet as adjuvant chemotherapy following complete resection of non-small-cell lung cancer (NSCLC) have been published, so this clinical study was designed to evaluate the toxicity profile and efficacy of the non-platinum doublet of docetaxel (DOC) + gemcitab...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-006-0391-6

    authors: Kawamura M,Eguchi K,Izumi Y,Yamato Y,Koike T,Sakaguchi H,Hada E,Kobayashi K

    更新日期:2007-09-01 00:00:00

  • A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck.

    abstract:PURPOSE:SU5416 is a novel small organic molecule that non-competitively inhibits the phosphorylation of the VEGF tyrosine kinase receptor, Flk-1. This phase IB study was performed to determine the safety, pharmacokinetics, and preliminary efficacy of the combination of SU5416 and paclitaxel in recurrent or metastatic c...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s00280-004-0871-5

    authors: Cooney MM,Tserng KY,Makar V,McPeak RJ,Ingalls ST,Dowlati A,Overmoyer B,McCrae K,Ksenich P,Lavertu P,Ivy P,Hoppel CL,Remick S

    更新日期:2005-03-01 00:00:00

  • Phenylbutyrate-induced apoptosis is associated with inactivation of NF-kappaB IN HT-29 colon cancer cells.

    abstract:PURPOSE:Cytotoxic chemotherapy has been used to treat patients with metastatic colorectal cancer with limited success. Therefore novel chemotherapeutic approaches are needed. Based on encouraging preclinical data, there has been an interest in developing derivatives of butyrate as clinically applicable agents. The purp...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-001-0390-6

    authors: Feinman R,Clarke KO,Harrison LE

    更新日期:2002-01-01 00:00:00

  • Reversal of multidrug resistance in Friend leukemia cells by dexniguldipine-HCl.

    abstract::Dexniguldipine-HCl (DNIG)--a prospective clinical modulator of p170-glycoprotein (pgp170)-mediated multidrug resistance (MDR)--was evaluated in a drug-accumulation assay in MDR murine leukemia cell strain F4-6RADR expressing pgp170. The compound elevated low accumulation of either doxorubicin (DOX), daunorubicin (DNR)...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00685872

    authors: Reymann A,Looft G,Woermann C,Dietel M,Erttmann R

    更新日期:1993-01-01 00:00:00

  • Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer.

    abstract:PURPOSE:To evaluate the feasibility, toxicity and efficacy of the combination of docetaxel and mitomycin C as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS:Thirty-eight patients with histologically confirmed, locally advanced or metastatic NSCLC were includ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-006-0198-5

    authors: Feliu J,Martín G,Castro J,Sundlov A,Rodriguez-Jaráiz A,Casado E,Lomas M,Madroñal C,Galán A,Belda C,Gonzalez-Barón M

    更新日期:2006-10-01 00:00:00

  • Renal function in the elimination of oral melphalan in patients with multiple myeloma.

    abstract::Pharmacokinetic studies in 11 patients with multiple myeloma were undertaken on the first and last days of one course of chemotherapy. The drug was administered PO in single doses of 6-14 mg daily. Melphalan concentrations were determined by high-performance liquid chromatography. The interpatient variability of pharm...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00306752

    authors: Adair CG,Bridges JM,Desai ZR

    更新日期:1986-01-01 00:00:00

  • Inhibition of glutathione synthesis reverses Krüppel-like factor 4-mediated cisplatin resistance.

    abstract:PURPOSE:To explore the protective effect of KLF4 against cytotoxicity induced by cisplatin and its possible mechanisms. METHODS:The expression levels of KLF4 were detected by RT-PCR and western blot in cancer stem-like cells derived from hepatocarcinoma (T3A-A3) and the hepatocarcinoma cell line HepG2. KLF4 was knocke...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-011-1708-7

    authors: Jia Y,Zhang W,Liu H,Peng L,Yang Z,Lou J

    更新日期:2012-02-01 00:00:00

  • Population pharmacokinetics meta-analysis of plitidepsin (Aplidin) in cancer subjects.

    abstract:OBJECTIVE:To characterize the population pharmacokinetics of plitidepsin (Aplidin) in cancer patients. METHODS:A total of 283 patients (552 cycles) receiving intravenous plitidepsin as monotherapy at doses ranging from 0.13 to 8.0 mg/m(2) and given as 1- or 24-h infusions every week; 3- or 24-h infusion biweekly; or 1...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,meta分析

    doi:10.1007/s00280-008-0841-4

    authors: Nalda-Molina R,Valenzuela B,Ramon-Lopez A,Miguel-Lillo B,Soto-Matos A,Perez-Ruixo JJ

    更新日期:2009-06-01 00:00:00

  • Dichloroacetate metabolically targeted therapy defeats cytotoxicity of standard anticancer drugs.

    abstract:PURPOSE:The observation that the orphan drug dichloroacetate (DCA) selectively promotes mitochondria-regulated apoptosis and inhibits tumour growth in preclinical models by shifting the glucose metabolism in cancer cells from anaerobic to aerobic glycolysis attracted not only scientists', clinicians' but also patients'...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-010-1361-6

    authors: Heshe D,Hoogestraat S,Brauckmann C,Karst U,Boos J,Lanvers-Kaminsky C

    更新日期:2011-03-01 00:00:00

  • SCMCIE94: an intensified pilot treatment protocol known to be associated with cure in CD 56-negative non-pelvic isolated Ewing sarcoma (EWS) is also associated with no early relapses in non-metastatic extremity EWS.

    abstract:PURPOSE:We report the unexpected absence of early relapse (before 30 months) in 24 consecutive patients with isolated limb primary Ewing sarcoma treated with an intensified pilot protocol, SCMCIE94. METHODS:Clinical data for the study were collected retrospectively from the patient files. The protocol included 6 cours...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-019-03789-3

    authors: Cohen IJ,Toledano H,Stein J,Kollender Y,Fenig E,Konen O,Bar-Sever Z,Issakov J,Feinmesser M,Avigad S,Ash S

    更新日期:2019-05-01 00:00:00

  • Physicochemical and pharmacokinetic parameters of seven lipophilic chlorambucil esters designed for brain penetration.

    abstract::This report describes the physicochemical and pharmacokinetic parameters of seven chlorambucil esters, which were compared with those of chlorambucil. These esters were designed as chlorambucil prodrugs to increase the brain penetration and concentration vs time profile of chlorambucil within the CNS for potential tre...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00686229

    authors: Greig NH,Genka S,Daly EM,Sweeney DJ,Rapoport SI

    更新日期:1990-01-01 00:00:00

  • Pharmacokinetics of neamine in rats and anti-cervical cancer activity in vitro and in vivo.

    abstract:OBJECTIVE:To study the pharmacokinetics of neamine in rats and to evaluate its anti-cervical cancer activity. METHODS:The plasma level of neamine was determined by HPLC-ELSD. Pharmacokinetic parameters were calculated using DAS 2.0 software. Tissue microarray analysis was conducted to examine angiogenin (ANG) expressi...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-014-2658-7

    authors: Liu Y,Zhang X,An S,Wu Y,Hu G,Wu Y

    更新日期:2015-03-01 00:00:00

  • Comparative brain and plasma pharmacokinetics and anticancer activities of chlorambucil and melphalan in the rat.

    abstract::Equimolar doses of chlorambucil and melphalan (both 10 mg/kg) were administered i.v. to anesthetized rats, and the plasma and brain concentrations of chlorambucil, its metabolites 3,4-dehydrochlorambucil and phenylacetic mustard, and melphalan were determined by high-performance liquid chromatography from 5 to 240 min...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00262729

    authors: Greig NH,Sweeney DJ,Rapoport SI

    更新日期:1988-01-01 00:00:00

  • Brain tumor-targeted delivery and therapy by focused ultrasound introduced doxorubicin-loaded cationic liposomes.

    abstract::Brain tumor lacks effective delivery system for treatment. Focused ultrasound (FUS) can reversibly open BBB without impacts on normal tissues. As a potential drug carrier, cationic liposomes (CLs) have the ability to passively accumulate in tumor tissues for their positive charge. In this study, FUS introduced doxorub...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-015-2926-1

    authors: Lin Q,Mao KL,Tian FR,Yang JJ,Chen PP,Xu J,Fan ZL,Zhao YP,Li WF,Zheng L,Zhao YZ,Lu CT

    更新日期:2016-02-01 00:00:00

  • A highly sensitive enzyme-linked immunosorbent assay for etoposide using beta-D-galactosidase as a label.

    abstract::A highly sensitive enzyme-linked immunosorbent assay (ELISA) for etoposide (EP) was developed, which is capable of accurately measuring as little as 40 pg EP/ml. Anti-EP sera were obtained by immunizing rabbits with EP conjugated with mercaptosuccinyl bovine serum albumin (MS.BSA) using N-[beta-(4-diazophenyl)ethyl]ma...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00689094

    authors: Saita T,Fujiwara K,Kitagawa T,Mori M,Takata K

    更新日期:1990-01-01 00:00:00

  • Intensive chemotherapy for adult lymphoblastic lymphomas.

    abstract::A total of 20 adults patients presenting with previously untreated lymphoblastic lymphoma underwent an intensive chemotherapy protocol. Either the BACOP or the m-BACOD regimen was used for induction. If the patients achieved a complete clinical remission (CR) after three courses, they were given intensive consolidatio...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00686341

    authors: Liang R,Todd D,Chan TK,Chiu E,Lie A,Ho FC,Loke SL

    更新日期:1991-01-01 00:00:00

  • In vitro succinate dehydrogenase chemosensitivity of gastric carcinoma--relationship to DNA content.

    abstract::Relationships between in vitro chemosensitivity and cell nuclear DNA content were investigated in malignant cells from 41 patients exhibiting advanced gastric carcinoma. The chemosensitivity was evaluated by measuring the succinate dehydrogenase (SD) activity in drug-exposed cancer cells and the DNA content was micros...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00686250

    authors: Saito A,Korenaga D,Maehara Y,Baba H,Okamura T,Sugimachi K

    更新日期:1992-01-01 00:00:00

  • Radioenhancement by cisplatin with accelerated fractionated radiotherapy in a human tumour xenograft.

    abstract::The aim of the present study was to investigate whether cisplatin would enhance the radioresponse of a human tumour xenograft when given in different schedules combined with accelerated fractionated radiation therapy. A human squamous carcinoma of the hypopharynx, FaDu, was grown in the thigh of athymic nude mice. Tum...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s002800050699

    authors: Joschko MA,Webster LK,Bishop JF,Groves J,Yuen K,Olver IN,Narayan KN,Ball DL

    更新日期:1997-01-01 00:00:00